What to expect as the virus continues

--  |   08/04/2020 Text size  Decrease  Increase   |  
email_fwd
<p>As the coronavirus continues to spread and impact both the health of humanity and the economy, our healthcare strategist, Karen Andersen, sat down with director of personal finance Christine Benz to share her analysis of the impacts and government response. More states have issued stay-at-home orders, and more than 100,000 tests are being performed every day in efforts to reduce the number of cases as well as restrictions. A recent&nbsp;<a href="https://www.morningstar.com/articles/971254/morningstars-view-the-impact-of-coronavirus-on-the-economy">paper by Andersen and equity analyst Preston Caldwell</a>&nbsp;highlights several treatments in clinical trials for an effective treatment for the virus.&nbsp;&nbsp;<br /><br />While the waves of the virus and social distancing measures are projected to continue into the second half of the year, the economic impact is not expected to be long term. Maintaining social distancing measures to contain the virus is the main priority--along with the ability to use various apps to track the locations of people who have contracted the virus. Technology is imperative during the quarantine as businesses work remotely and research on the virus continues. On that same note, limitations are present: the shortage of ventilators and beds in the ICU. Companies are trying to respond quickly to increase capacity, but it is likely that the virus may overlap them. The worst wave is expected to hit in April. Improvement at the beginning of May can be expected if social distancing orders are obeyed, possible treatments continue to be tested, and the capacities of hospitals increase.&nbsp;</p> <p><em>Please stay tuned for important disclosure information at the conclusion of this video.</em></p> <p><strong>Christine Benz:</strong>&nbsp;Karen Andersen, who's a strategist in equity and credit research was with us&nbsp;<a href="https://www.morningstar.com/articles/972435/market-economic-implications-amid-latest-virus-news">three weeks ago</a>. She's back today and she's going to kick things off for us by providing an updated view on where we stand in terms of stopping the spread of the virus as well as the economic implications. So Karen will discuss developments that she and the team are seeing in terms of testing and vaccinations, therapies, as well as some of the equipment shortages that we've seen in the healthcare arena.</p> <p>Karen, please take it away.</p> <p><strong>Karen Andersen:</strong>&nbsp;Thanks Christine. Now that we have more information on how a coronavirus is spreading in different countries and more information on how governments are responding, my equity research colleague Preston Caldwell and I have updated our March 9 analysis. So our new report was published Tuesday, and it really tries to dive a little deeper into how this virus is affecting our health and our economy. So as far as health, we've refined our U.S. scenarios to get a month-by-month forecast of how the infection could spread and how widely the social distancing measures will be spread across the states.&nbsp;</p> <p>Just first, maybe a few updates on what we're doing to slow the spread of the virus right now. Almost half of Americans were under stay-at-home orders as at the end of March. And I believe that that dramatically increased in the past two days, as we've seen several more states issuing these kinds of orders. Our access to diagnostics is improving rapidly. So we now have more than a hundred thousand tests being performed each day in the U.S. so that brought us from March, I think, up to a million tests total. Both of these facts lead us to believe that our current efforts are allowing us to begin to reduce the number of cases possibly by early May and begin to slowly lift restrictions this summer, June and July. We do think we'll have confirmation of at least one effective treatment during the summer, which should give us more confidence even if we start to see some outbreaks again as we lift these restrictions, we won't see a replay of the shortages that we're currently seeing with ventilators in New York.&nbsp;</p> <p>Maybe just a little bit more on the treatment. So, the FDA actually just did sign off on March 28th on emergency use of two versions of an antimalarial drug to treat coronavirus. These drugs appear to act as antivirals in this case, and they have supportive data in some small studies so far. So hydroxychloroquine is being used widely in hospitals to help healthcare workers stay healthy and to treat patients as part of clinical trials or with this emergency approval. But there are also several other treatments that are now in clinical trials that we've updated in our new report. So Gilead's remdesivir remains the leading hope for an effective treatment, with data expected later this month from controlled studies in China, data from a handful of patients in different countries for remdesivir so far has been encouraging, but it's not definitive. So we're waiting for these studies that have a control arm to give us more indication. We model a 70% probability of approval for that drug.&nbsp;</p> <p>Two arthritis therapies are now also in clinical trials. These could help very sick patients with lung inflammation recover more quickly or avoid a ventilator, which is very important if we're facing these kinds of shortages. These therapies are widely available, and they could be quickly repurposed for coronavirus. And they only would require one dose that is being used in trials versus arthritis patients who typically require a dose every couple of weeks. Then in the long run, the pipeline is starting to shape up with the potential also for more-targeted drugs that are specifically designed against coronavirus by the end of the year and then vaccines in early 2021. I think JNJ was one of the latest firms that talked about accelerating their vaccine timelines, and they've guided now to an early 2021 time frame. That would be really roughly a one-year development time for a vaccine, and that would be at the faster end of that 12 to 18 months that a lot of companies have cited for coming up with a vaccine.</p> <p>The way I'm looking at this is that we will have waves of the virus and additional social distancing waves in the second half of the year, but not at the level of what we're doing right now, given the future availability of treatments. In addition, we'll have waves of new treatments after that, starting with repurposed drugs, Gilead's drug, targeted antibodies, and then ultimately a vaccine in 2021.&nbsp;</p> <p>Just very briefly turning to the economic impact. Our conclusions here are fairly similar to our previous report. We did increase the GDP impact we model for 2020, and we do now assume a 2.4% contraction in GDP in our base case. But we think the scope of the shutdown to disrupt the U.S. economy long-term is likely overrated. About 70% of GDP is actually from businesses that are mostly exempt from orders, and half of the businesses that aren't exempt can continue with remote operations. Also the fiscal stimulus should prevent a collapse on demand of the U.S. economy. That's our really our latest take on overall health and economic impact, Christine.</p> <p><strong>Benz:&nbsp;</strong>Karen, question for you: In terms of vaccines and therapies, let's talk about your sort of bear case if things don't unfold as you expect them to in the second half of the year.&nbsp;</p> <p><strong>Andersen:</strong>&nbsp;In a bear-case scenario, we do assume that there would be no effective treatment. And we also assume that we would be struggling a bit more to try to contain it even with this kind of first pass of social distancing measures. The other fact is that if we are struggling and there are no treatments, there's really only so long that we can try to hold on to this really aggressive shutdown of the country. I think that that probably would be limited to a few months as opposed to a year shutdown of the entire country.&nbsp;</p> <p>I do think that one thing that's important to remember, though, in this kind of scenario is the kind of tools that have been used in certain countries in Asia to prevent and control outbreaks. I'm thinking of countries like South Korea and Singapore. So what they do is they actually very aggressively trace contacts of those who become infected and then quarantine those who may have been exposed. And so now, just recently there's really been kind of an explosion in technology to help with this. And so there are various apps that can be used to track locations and then really determine who was close enough to someone who became infected that they need to self-quarantine. So this sort of information is really critical. Especially if we're in a situation where we've already contained the virus, and we're trying to emerge from a lockdown, and we don't have any kind of effective treatment.&nbsp;</p> <p>A big question here, though, is whether Americans are willing to accept the kind of privacy rights' violation issues that would come with this. I think one solution, though, could be to make these apps voluntary. And so if the situation remains really dire, I would hope that we would see a lot of folks volunteering to allow their maybe anonymized location data to be shared. So I think that even if we're really struggling with some of the social distancing measures, and even if we're not sure which treatment is best, I think there's probably a lot we can start to do, a progress we can make with technology, assuming Americans can get on board with this and start using their phones as something to help us fight the disease.</p> <p><strong>Benz:</strong>&nbsp;Karen, question for you about these ventilator shortages, which you briefly mentioned. Can you discuss your thoughts about how that will unfold in the coming months if these shortages aren't just limited to New York but other cities as well?</p> <p><strong>Andersen:</strong>&nbsp;Yeah, sure, Christine. New York, as of the data that we had on Tuesday, that was about 40% of U.S. cases and I think about 20% of all U.S. cases were in New York City alone. Having so many cases centered in one region or one city is frightening. There are so many limitations on what the healthcare system can handle from the number of ventilators, to even the number of healthcare workers trained to monitor patients on ventilators, to the number of ICU beds that these patients might need. We're seeing ventilator manufacturers trying to quickly increase capacity. Most of these companies are looking at something on the order of doubling their capacity. But this isn't really likely to come fast enough for this worst of the wave that's hitting us in April. But in our base- and bull-case scenarios, both of those scenarios, we think a ramped-up production of ventilators, potential new treatments, and better containment could all help improve the situation beginning in May.</p> <p>There are also a lot of creative ways that supply could be boosted faster. The FDA has already taken some steps here. They're allowing sleep apnea positive airway machines to be used in severe coronavirus patients. They're also using tube splitters, so that allows patients to share ventilators. Then also we've seen industries volunteer to make simplified ventilators that I wouldn't have really considered like auto industry or Dyson, the expert in vacuums. April will likely be very tough. But there are several ways that we can improve supply and reduce demand by having treatments beyond April.</p> <p><em>&copy;2020 Morningstar, Inc.. All Rights Reserved. The Morningstar name and logo are registered marks of Morningstar, Inc.</em></p> <p><em>This video contains certain forward-looking statements. We use words such as &ldquo;expects&rdquo;, &ldquo;anticipates&rdquo;, &ldquo;believes&rdquo;, &ldquo;estimates&rdquo;, &ldquo;forecasts&rdquo;, and similar expressions to identify forward-looking statements. Such forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause the actual results to differ materially and/or substantially from any future results, performance or achievements expressed or implied by those projected in the forward-looking statements for any reason.</em></p> <p><em>The information in this video is for informational purposes only and has no regard to the specific investment objectives, financial situation or needs of any specific recipient. This video is intended to provide information to assist investors in making their own investment decisions, not to provide investment advice to any specific investor. Therefore, investments discussed and recommendations made herein may not be suitable for all investors: recipients must exercise their own independent judgment as to the suitability of such investments and recommendations in the light of their own investment objectives, experience, taxation status and financial position.</em></p> <p><em>Opinions expressed are as of date this video was recorded; such opinions are subject to change without notice. Morningstar and its subsidiaries shall not be responsible for any trading decisions, damages, or other losses resulting from, or related to, the information, data, analyses or opinions or their use. The information, data, analyses, and opinions presented herein do not constitute investment advice, are provided solely for informational purposes and therefore are not an offer to buy or sell a security. Please note that references to specific securities or other investment options within this piece should not be considered an to purchase or sell that specific investment.</em></p> <p><em>It is important to note that investments in securities involve risk and will not always be profitable. There can be no assurance that any financial strategy will be successful.</em></p> <p><em>Christine Benz is an employee of Morningstar, Inc.</em></p> <p><em>Karen Andersen is an employee of Morningstar Research Services LLC. Investment research is produced and issued by subsidiaries of Morningstar, Inc. including, but not limited to, Morningstar Research Services LLC, registered with and governed by the U.S. Securities and Exchange Commission. The opinions expressed are given in good faith, are as of the date this video was recorded, and are subject to change without notice. The analysis presented are statements of opinions; they are not statements of fact. Analysts have made a reasonable effort to carefully research information contained in the video.</em></p> <p><em>The information on which the analysis is based has been obtained from sources believed to be reliable. While the data, statistics and information were obtained from sources it believes to be reliable, neither the Research group nor Morningstar, Inc. performs an audit or seeks independent verification of any of the data, statistics, and information it receives.</em></p> <p><em>The information contained in this video is the proprietary material of Morningstar. Reproduction, transcription, or other use, by any means, in whole or in part, without the prior written consent of Morningstar, is prohibited.</em></p>

Video Archive...

2 US wide-moat stocks to buy on a dip
16/04/2021  Amazon.com and ServiceNow are looking increasingly attractive.
Fidelity's Kate Howitt names her 3 top stocks for 2021
15/04/2021  Investment tips from Australian equities fund manager Kate Howitt.
Back to basics: What is income investing?
14/04/2021  What is income investing, why is it important and which investors should focus on it? Morningstar Investment Management's Dan Kemp has the answers.
Hunting for pockets of value in an overheated market: Morningstar
13/04/2021  Morningstar equity strategist Gareth James discusses the great value rotation, why he believes the Australian share market is overvalued and where opportunities still lie for hungry investors.
Vaccine rollout drives energy's rise
12/04/2021  But the sector's current tailwinds are likely unsustainable, so investors should prioritise high-quality businesses with stable balance sheets, says Morningstar's Dave Meats.
Finding value with Kate Howitt
08/04/2021  Kate Howitt oversees Fidelity’s Australian Opportunities fund. She discusses her investing approach, the outlook and where she sees value.
Investing for millennials
07/04/2021  Goldman Sachs's Laura Destribats talks about the millennial investment trend, and why tech and experiences are so important to this generation.
What if I want to buy Bitcoin?
06/04/2021  Remember that the returns on speculative assets like Bitcoin are high risk
EGG, SGF, ZBRA: Foraging for the unloved gems
01/04/2021  Steve Johnson explains why Forager Funds Management has bought and held Enero, SG Fleet and Zebra Technologies and why they're poised for further growth.
Why the 'covid spending economy' will flourish
30/03/2021  Forager's Steve Johnson explains why he's bullish on consumer spending, enterprise software companies, and why he has cashed in on big names like Uber.
Proteomics set for growth, says Kardinia
29/03/2021  Kristiaan Rehder explains why the West Australian biotech is among the top performers in the Bennelong Kardinia Capital Absolute Return Fund.
Should you be worried about inflation?
26/03/2021  And how to make inflation "personal."
Crypto what?
25/03/2021  The how, what, and why of cryptocurrency.
The long and short of an absolute return fund
24/03/2021  An absolute return fund aims to seek returns in all weather. Kristiaan Rehder from Bennelong Kardinia Capital explains how.
3 dividend-paying real estate stocks for your watchlist
23/03/2021  Diversified portfolios, strong balance sheets and healthy payouts. Grant Berry singles out three big contributors to the SG Hiscock Property Income Fund.
AREITs in the time of covid
22/03/2021  SG Hiscock's Grant Berry explains how real estate was affected by the pandemic, how property stocks coped, and the chase for income in an evolving retail landscape.
Have we reached peak video gaming?
19/03/2021  Video gaming has soared under lockdown, can this sector keep growing post-covid? Morningstar analyst Neil Macker takes a look.
Myer: five stars and poised for the rebound
18/03/2021  The retail giant's strong balance sheet will help it navigate the shift to online shopping and capitalise on the return to normal life, says Morningstar's Johannes Faul.
Deliveroo IPO: what you need to know
10/03/2021  Ahead of Deliveroo's IPO, Morningstar analyst Ioannis Pontikis looks at the outlook for the business, its valuation and concerns about gig workers.
2 stocks for the e-learning boom
08/03/2021  E-learning has become the norm for young students and university-goers across the world. Morningstar analyst Michael Field looks at whether the trend is here to stay. 
February Reporting Season Wrap Up with Peter Warnes: Webinar
04/03/2021  Special guest Peter Warnes, our head of equities research, joins the Morningstar Foundations of Investing Webinar series to give his unique take on February Reporting Season and answer subscriber questions.
One year after the market crash, through the ETF lens
03/03/2021  The growth and adoption of exchange-traded funds has only accelerated as a result of the latest market crisis.
Brighter picture for big four banks
01/03/2021  Morningstar's Nathan Zaia on the outlook for the banks, dividend payouts and the move by the Bank of Queensland to acquire ME Bank.
One year on: lessons learned from the 2020 bear market
25/02/2021  The biggest takeaway from that period is not to panic when the market tumbles.
What if...I want to buy a gold ETF?
23/02/2021  From ETFs backed by bullion to miners with more upside potential - here's how to get yourself some gold.
'Full return to normal in 2021'
23/02/2021  If the US is to stage a recovery by mid-year, it will need the consumer services sector to fire, says Morningstar's head of economic research Preston Caldwell.
Google, Facebook versus Aussie news stocks
19/02/2021  Morningstar's Brian Han weighs up News Corp's deal with Google and examines the effect of Facebook's decision to block content from Australian media outlets.
Global real estate as a store of value
18/02/2021  Quay Global Investors' Chris Bedingfield explains how self-storage, data centres and industrial property can offer diversification and growth.
Spotting the 'covid winners'
16/02/2021  Uniti Group and Nextdc are among the companies that SG Hiscock's Hamish Tadgell says have flourished during the pandemic.
The transition from hope to growth
15/02/2021  Hamish Tadgell of SG Hiscock explains the portfolio changes he’s made in a bid to capitalise on the shift.
The future of the US economy
10/02/2021  Which pandemic-related trends have already passed, and which ones might be around the corner?
GameStop frenzy is history repeating
05/02/2021  The battle between the Reddit army and hedge funds is nothing new—the question is will regulators be willing to step in, says Morningstar's John Rekenthaler.
Who are the fast fashion winners?
03/02/2021  Competition is fierce for fast fashion retailers such as Asos, H&M, Zalando and Inditex. Morningstar analyst Jelena Sokolova takes a look at the sector.
Can your portfolio withstand volatile times?
01/02/2021  Volatility can be around any corner, says Morningstar director of personal finance Christine Benz.
How much equity exposure is too much in retirement?
28/01/2021  Retirees require stocks' growth potential, but they need a cash and bond buffer, too.
Key trends for China investors
27/01/2021  Rebecca Jiang, manager of the JPMorgan China Growth & Income Trust, looks at why Chinese stocks soared in 2020 and whether the trend can continue.
Redpoint's 3 top picks in industrials
25/01/2021  Redpoint's chief executive and portfolio manager Max Cappetta tells Lex Hall why he's got his eye on JB Hi-Fi, Goodman and Reliance Worldwide in 2021.
Looking for growth and income among industrials
21/01/2021  Redpoint CEO and portfolio manager Max Cappetta looks at the dividend potential of large-cap names, the resilience of Qantas, and the local tech landscape.
What we expect from oil prices
19/01/2021  Stocks still look cheap across all subsectors, especially oilfield services and refining, says Morningstar analyst Dave Meats.
What’s app-ening: investing from your phone
19/01/2021  What are the rewards and risks of using this technology?
A Democrat clean sweep and corporate America
15/01/2021  Morningstar's head of policy research Aron Szapiro explains what sort of changes a Biden government will make and how they will affect company valuations.
3 stocks for climate transition
14/01/2021  Freight-rail, building temperature efficiency, and carmaking are among the sectors Aviva Investors' Jaime Ramos Martin has his eye on.
The outlook for dividends
13/01/2021   Dividend investors had a hard time in 2020, but Morningstar analyst Dan Lefkovitz think the outlook is brighter for the year ahead.
3 themes for fund investors in 2021
11/01/2021  Morningstar Investment Management's Dan Kemp reveals the three investment themes on his mind for the year ahead.
What next for oil and gas companies?
06/01/2021  Morningstar equity analyst Allen Good looks at the prospects for oil and gas giants in the year ahead. 
China outlook 2021
05/01/2021  China had a strong year after a rocky start, but can it continue—and what does a US President Biden mean for the region? Morningstar analyst Lorraine Tan explains.
Tech, travel and trends for 2021
04/01/2021  Morningstar equity director Alex Morozov considers the outlook for tech, travel and beyond for the year ahead.
Money and investment lessons of 2020
01/01/2021  How to plan for things you can't plan.
Morningstar Year in Review 2020
25/12/2020  2020: we look back at the highs and lows of an unprecedented year in financial markets and explore the themes shaping 2021.
Are music streaming companies a big hit with investors?
22/12/2020  Music streaming companies have seen stellar growth in user numbers. We ask Morningstar equity analyst Neil Macker if the trend can continue.
What Tesla's inclusion in the S&P 500 means for investors
21/12/2020  While it stands as the largest addition in the index's history, this likely won't impact everyday investors all that much. 
Peter Warnes and the 2021 Forecast
18/12/2020  Will there be opportunities to deploy cash in the new year? Will there be a reprieve from covid? And what will the incoming Biden administration mean for markets?
Investing in the climate transition
18/12/2020  Companies that specialise in solar, building efficiency and renewables underpin Aviva Investors' Climate Transition Global Equity Fund, says Jaime Ramos Martin.
Why does liquidity matter?
16/12/2020  Why does liquidity matter to investors, and how can it affect your returns? Morningstar equities director Tom Whitelaw explains.
Introducing the Morningstar Capital Allocation Rating
14/12/2020  Learn what we look for when rating a company.
Incorporating ESG into our equity research process
14/12/2020  Morningstar's new approach unpacks the environmental, social and governance risks that companies face.
Tagliaferro: yield ideas for your portfolio
10/12/2020  Industrial companies typically generate better cash flows and can offer a steady income stream, says the IML founder.
Anton Tagliaferro on value versus growth
09/12/2020  The lofty valuations of Tesla and Afterpay typify the effervescence and speculation in the market, says the IML founder.
Can car companies be ESG investments?
08/12/2020  Car makers may not be an obvious investment choice for ESG-conscious investors, but Morningstar analyst Tancrede Fulop says some of the largest companies score highly in some measures such as safety and human capital.
The US and China under president-elect Biden
07/12/2020  Janus Henderson's Matt Peron considers how the relationship between the US and China will evolve under a President Biden.
Investing basics: what is active and passive investing?
04/12/2020  What is active investing, and what is passive investing? We're at the whiteboard to explain the pros and cons of each 
Why we still like Treasury Wine
04/12/2020  Treasury Wine Estates remains an undervalued stock in spite of China's demand-destroying tariff on Australian wine. Morningstar director of equity research Adam Fleck explains why.
What is gold worth?
03/12/2020  And do any other assets currently compare?
Why now is the time for ESG investing
02/12/2020  We're at an inflection point in ESG investing, says Sustainalytics founder Michael Jantzi. Here's why. 
10 stocks retail investors bought in covid sell-off
01/12/2020  Beaten-down travel stocks and BNPL providers featured heavily, says nabtrade’s Gemma Dale.
How retail investors seized on covid sell-off
30/11/2020  Many people were waiting for the opportunity to buy shares at historic discounts, says nabtrade’s Gemma Dale.
AMP: difficulties now, but dividends later
27/11/2020  The 171-year-old wealth manager has had its scandals but there's merit to its turnaround strategy and the quality of its other assets, says Morningstar's Shaun Ler.
'Be careful using buy now pay later'
27/11/2020  BNPL products such as Zip Co help boost consumer spending but they come with risks and are overvalued, says Morningstar analyst Shaun Ler.
Hamish Douglass: Winners and losers in the covid era
26/11/2020  The Magellan co-founder argues the ecommerce acceleration is here to stay and ponders the effect it will have on other sectors such as travel and commercial real estate.
A 'wonderful hunting ground'
25/11/2020  Greg Dean of Cambridge Global Asset Management explains why the consumer services sector has yielded healthy returns.
Hamish Douglass and big tech
25/11/2020  Magellan's co-founder explains which tech behemoth the Magellan Global Fund no longer owns, why one was too tricky to value, and why regulation is no threat.
Hamish Douglass: 'We're lucky this pandemic hit when it did'
24/11/2020  Magellan's co-founder on why 2020 resembles 2000 and why covid-19 is a dry run for something that could be much worse without proper planning.
Should you beef up your exposure to meat processors?
23/11/2020  Their shares have gotten hammered this year. Are they opportunities or value traps?
What is the Morningstar ESG Commitment level?
20/11/2020  Our new rating highlights the degree to which a fund or asset manager considers environmental, social, and governance issues.
What's driving the flows into ESG funds
19/11/2020  Morningstar's Grant Kennaway explains why sustainable funds are increasingly popular and why they're performing well. 
Too much upside baked into Bunnings: Morningstar
17/11/2020  Morningstar director of equity research Johannes Faul looks at home improvement retailer Bunnings.
What is ESG?
16/11/2020  From climate change to workers' rights, ESG is a big part of the investing world. We're at the Morningstar whiteboard board to explain what it means and why it matters.
"I'm still cautious": Peter Warnes' best ideas for income investors
12/11/2020  We're not out of the woods yet, says our head of equity research, as he looks for safety in businesses we can't live without and shies away from the banks. 
Is it time to get exposure to China?
11/11/2020  Perhaps it is time to have exposure to this economic powerhouse and its 1.4 billion population, says Morningstar's Peter Warnes.
Tapping into the contactless spending boom
10/11/2020  What happens when you buy something when your bank card? Morningstar analyst Niklas Kammer explains which companies are benefiting from your transaction.
Can luxury stocks recover from covid?
09/11/2020  With travel bans and economic lockdowns, the luxury sector has been hit hard in 2020. But there are still opportunities, says Morningstar analyst Jelena Sokolova.
US election scenarios and what they mean for investors
05/11/2020  A discussion of taxes, stimulus, regulation, and the likely market reaction as results from the 2020 poll come in. 
Don't try to time elections
03/11/2020  Why you should resist the urge to make predictions when there's a disconnect between the economy and security prices.
3 names on the alternative protein shelf
02/11/2020  Etoro analyst Josh Gilbert shares his thoughts on Beyond Meat and two other companies making inroads into the plant-based meat sector.
Hamish Douglass: I'd be super surprised if Trump won
30/10/2020  The Magellan rainmaker explains why he doubts the Republican leader will prevail and why investors should brace for volatility—and ignore it. 
Gauging the appetite for alternative protein
29/10/2020  The market for plant-based meat is worth $14bn today and is expected to grow massively, says eToro's Josh Gilbert.
Browsing the opportunities aisle in retailing
28/10/2020  Morningstar equity analyst Johannes Faul explores the flipside to the surge in growth in online sales.
3 top Asian picks on Longlead's radar
22/10/2020  China and Hong Kong have been a happy hunting ground, says Longlead Capital Partners' co-founder Andrew West, who singles out tech, pharmaceuticals and power tools.
3 undervalued travel stocks we like
22/10/2020  These names stand to benefit from a resumption of leisure travel - and are all trading below our fair value estimates.
3 reasons to like bonds
20/10/2020  Morningstar's Mark Preskett looks at three reasons why bonds are an important tool in your investment portfolio.
The monopoly asset that could boost Link
19/10/2020  A bigger stake in the online conveyancer PEXA could be the key to increasing Link Administration's revenue, says Morningstar's Gareth James.
How Longlead Capital defied the covid plunge
16/10/2020  Longlead Capital Partners co-founder Andrew West reveals how his Asia-focused fund managed to make gains during the historic covid-19 sell-off.
Investing basics: why invest in bonds?
16/10/2020  The investment board is back with an explainer on why you might invest in bonds.
Retiring during a pandemic
13/10/2020  How to handle this decision—even when it is made for you.
3 top picks in sustainability and software
12/10/2020  Nick Griffin of Munro Partners reveals why and where he sees opportunities in renewable energy, diagnostics and software. 
Investing basics: what's your personal inflation rate?
09/10/2020  Take stock of your spending to determine if inflation is an issue for you.
Ant Group IPO: What you need to know
09/10/2020  Morningstar analyst Chelsey Tam explains why investors are excited about the flotation of Ant Group and why it's different from Alibaba.
Spotting the winners of tomorrow
06/10/2020  Companies that address the growing demand for decarbonisation will have a 20-year growth opportunity, says Nick Griffin of Munro Partners.
An interview with Whitehaven Coal chief Paul Flynn
30/09/2020  EXCLUSIVE EXTRACT: Morningstar's Mat Hodge and Lex Hall talk to the CEO of the independent producer and exporter about the company's fortunes and its future.
How to get rich slowly
30/09/2020  Slow and steady wins the financial race.